Adma Biologics Inc (ADMA) Growth Rates Comparisons to Biotechnology & Pharmaceuticals Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Competitors, else..
 
Adma Biologics Inc   (NASDAQ: ADMA)
 

Adma Biologics Inc Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ADMA Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) 5.59 % 5.15 % 10.18 % 10.9 %
Q / Q Revenue Growth (Q3 MRQ) 13.43 % -11.92 % -2.46 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 6.56 % 5.66 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q3 TTM) 1.46 % 1.16 % 2.1 % 2.61 %
Revenue 5 Year Average Growth 64.6 % 8.24 % 8.67 % 13.63 %


ADMA's Growth Comparisons in III. Quarter 2026




Softening Adma Biologics Inc 's 5.59% year on year Revenue improvement, in the third quarter 2026 to 141 millions, outgrows the 5.15% growth in the Biotechnology & Pharmaceuticals industry, but Adma Biologics Inc 's growth compares unfavorably, to the 10.18% Revenue improvement in the Healthcare sector.

Top-line improved by 13.43% from the second quarter. Looking into annual sales rise of 64.6%, and S & P 500's average yearly sales growth is 13.63% over the five years, including only Businesses with the third quarter 2026 Results. Adma Biologics Inc grew faster than the market.

ADMA Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
ADMA Bio Manufacturing Segment
-
59.42 %
Intermediates and Other ADMA BioManufacturing
-
1.74 %
US
-
59.49 %
Non Us
-
12.82 %
Member
-
59.07 %
Plasma Collection Centers United States
-
50.7 %
Total
-
13.43 %


Growth Rates of ADMA's Income in the third quarter 2026


ADMA Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) 32.83 % 524.46 % 11.09 % 97.6 %
Sequential Operating Income Change (Q3 MRQ) 29.2 % -49.25 % -12.21 % 48.13 %
Y / Y Operating Income Growth (Q3 TTM) -9.85 % 996.78 % 30.98 % 40.67 %
Sequential Operating Income Growth (Q3 TTM) 10.35 % 230.05 % 4.93 % 20.86 %
Operating Income 5 Year Avg. Change - -18.52 % 10.27 % 18.8 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) 36.94 % -80.67 % -38.86 % 90.69 %
Sequential Income from Cont. Ops. Change (Q3 MRQ) 31.89 % - -63.27 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) -36.48 % -86.3 % 9.88 % 57.33 %
Sequential Income from Cont. Ops. Change (Q3 TTM) 11.25 % -58.35 % -4.67 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change - -11.53 % 8.91 % -28.64 %

ADMA Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) 36.94 % -82.09 % -39.2 % 90.69 %
Q / Q Net Income Growth (Q3 MRQ) 31.89 % -89.11 % 11.78 % 27.07 %
Y / Y Net Income Change (Q3 TTM) -12.91 % 102.94 % 15.43 % 57.33 %
Sequential Net Income Change (Q3 TTM) 7.96 % -7.86 % -6.73 % 18.65 %
Net Income 5 Year Avg. Growth - -8.71 % 9.09 % 23.95 %

ADMA's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) 46.67 % -83.01 % -38.86 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q3 MRQ) 29.41 % - -63.27 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) -10.23 % - - -
Sequential EPS from Cont. Ops. Change (Q3 TTM) 9.72 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth - 38.46 % 8.91 % -28.64 %



ADMA EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) 46.67 % -84.26 % -39.2 % -28.64 %
Q / Q EPS Net Growth (Q3 MRQ) 37.5 % -89.98 % 11.78 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q3 TTM) 10 % - 10.63 % 4.93 %
EPS Net 5 Year Avg. Change - -8.71 % 9.09 % 23.95 %



Adma Biologics Inc showed impressive 46.67% year on year rise in the third quarter to $0.22, despite the -84.26% inBiotechnology & Pharmaceuticals industry, Healthcare sector dropped -39.2%. Slow third quarter 2026 income per share, in Biotechnology & Pharmaceuticals industry and Healthcare sector, were portrayed in the Adma Biologics Inc results which underperformed overall market.

The company's sequential bottom-line increase was 37.5% from the second quarter. Average annual income per share rise for Adma Biologics Inc is 64.6%, while S & P 500's average yearly income per share growth is 23.95% over the five years, including only Businesses with the third quarter 2026 earnings results.

ADMA Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) - - 44.26 % 48.62 %
Sequential Free Cash Flow Change (Q3 MRQ) -43.92 % -53.34 % -42.65 % 34.18 %
Y / Y Free Cash Flow Change (Q3 TTM) 93.9 % 12.59 % 19.33 % 60.27 %
Sequential Free Cash Flow Change (Q3 TTM) 14.09 % 17.82 % 5.88 % 15.75 %
Free Cash Flow 5 Year Avg. Change - -13.84 % 0.41 % 1.8 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q3 MRQ) - 31.48 % - 216.68 %
Y / Y Net Cash Flow Change (Q3 TTM) - 783.99 % - 209.43 %
Sequential Net Cash Flow Change (Q3 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change - 23.25 % 6.46 % 1.07 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) -85.61 % 31.05 % 10.33 % 120.03 %
Sequential Capital Expenditures Change (Q3 MRQ) -8.33 % -4.21 % -19.32 % 36.87 %
Y / Y Capital Expenditures Change (Q3 TTM) -67.81 % 3.16 % 9.34 % 109.38 %
Sequential Capital Expenditures Change (Q3 TTM) -60.01 % 6.42 % 0.99 % 23.05 %
Capital Expenditures 5 Year Avg. Change 12.46 % 9.64 % 8.61 % 14.19 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.